Pathological response ≥90% predicts survival in HCC treated with neoadjuvant loco-regional therapies: A retrospective cohort study
This study has been registered at the Chinese Clinical Trial Registry (unique identifying number: ChiCTR2300076241, https://www.chictr.org.cn/showprojEN.html?proj=208162).
Authors
- Chao Zhang (ORCID: https://orcid.org/0000-0002-9891-0605)
- Li Xu (ORCID: https://orcid.org/0000-0003-4405-1048)
- Minshan Chen (ORCID: https://orcid.org/0000-0002-6741-7498)
- Li-Ying Ou-Yang
- Ming Shi (ORCID: https://orcid.org/0000-0002-4051-4474)
- Neng Jiang (ORCID: https://orcid.org/0000-0002-9778-5013)
- Ziliang Yang
- Yi‐Xiang Gan (ORCID: https://orcid.org/0000-0003-1794-6866)
- Jing‐Ping Yun
- Yao‐Jun Zhang (ORCID: https://orcid.org/0000-0001-8357-5544)
- Shi-Xun Lu
- Zhong-Guo Zhou
Institutions
- Sun Yat-sen University (CN)
- Sun Yat-sen University Cancer Center (CN)
Publication Details
- Journal
- JHEP Reports
- Published
- 2025-10-17
- DOI
- https://doi.org/10.1016/j.jhepr.2025.101638
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00